Julien Spatazza, PhD

Julien Spatazza has more than 15 years of research experience in both academic and pharma settings. Dr. Spatazza joined Coave Therapeutics in early 2023 as director of translational science. Previously, he was head of pharmacology at BrainEver, where he led the development of a homeoprotein-based platform for the treatment of Parkinson’s disease and ALS. Prior to his tenure at BrainEver, Dr. Spatazza worked as a scientist at Neurona Therapeutics, where he performed preclinical work showing that transplanted GABA interneurons derived from human stem cells can decrease seizure frequency in animal models of temporal lobe epilepsy, thus contributing to the initiation of a Phase I study in people with drug-resistant seizures. Dr. Spatazza holds a PhD from the University Pierre and Marie Curie (Paris VI) and performed postdoctoral studies at the University of California, San Francisco (USA). He is the author of 13 scientific articles.